Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Testing revenue	$ 7,249	$ 7,044	$ 13,704	$ 14,139
Product revenue	3,475	0	3,475	0
Collaboration, license and other revenue	11	85	118	205
Total revenue	10,735	7,129	17,297	14,344
Operating expenses:
Cost of testing	2,852	2,508	5,624	5,218
Cost of product	3,056	0	3,056	0
Research and development	3,143	2,510	6,302	3,931
Sales and marketing	3,356	2,526	5,093	4,549
General and administrative	5,393	2,329	11,070	5,034
Change in estimated fair value of contingent consideration	(97)	142	(310)	(111)
Total operating expenses	17,703	10,015	30,835	18,621
Loss from operations	(6,968)	(2,886)	(13,538)	(4,277)
Interest expense	(526)	(256)	(783)	(1,083)
Other expense	(274)	(43)	(3,200)	(97)
Change in estimated fair value of common stock warrant liability	(3,165)	0	(3,165)	0
Loss before income taxes	(10,933)	(3,185)	(20,686)	(5,457)
Income tax benefit	440	0	440	0
Net loss	(10,493)	(3,185)	(20,246)	(5,457)
Net loss attributable to noncontrolling interest	23	0	23	0
Net loss attributable to CareDx, Inc.	$ (10,470)	$ (3,185)	$ (20,223)	$ (5,457)
Net loss per share attributable to CareDx, Inc. (Note 3):
Basic and diluted	$ (0.77)	$ (0.27)	$ (1.58)	$ (0.46)
Weighted average shares used to compute net loss per share attributable to CareDx, Inc.:
Basic and diluted	13,568,120	11,835,405	12,768,913	11,824,993